Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.